Low-grade Gliomas in Older Patients: Long-term Follow-up from Mayo Clinic
Overview
Authors
Affiliations
Background: Low-grade gliomas (LGGs) are uncommon in older patients, and long-term clinical behavior and prognostic factors are not well defined in this group.
Methods: The authors retrospectively searched their tumor registry for the records of adult patients (> or =18 years) diagnosed as having nonpilocytic LGG between 1960 and 1992 at Mayo Clinic. The Kaplan-Meier method was used to estimate progression-free survival and overall survival (OS) in patients aged 55 years and older.
Results: Of 314 patients initially identified, 32 were aged at least 55 years, with a median age at diagnosis of 61 years (range, 55-74 years). Median follow-up was 17.3 years for survivors. Operative pathologic diagnoses comprised astrocytoma (n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%). Gross total resection was achieved in 1 patient, radical subtotal resection in 1, and subtotal resection in 14; 16 patients had biopsy only. Postoperative radiotherapy or chemotherapy was given to 23 (72%) patients and 1 (3%) patient, respectively. Median OS was 2.7 years for all patients: 3 years with resection and 2.2 years with biopsy only (P = .58). The 5- and 10-year OS rates were 31% and 18%, respectively. Factors adversely affecting OS on univariate analysis were enhancement on computed tomography (P < .001) and supratentorial location (P = .03).
Conclusions: This retrospective series of older patients suggests that intracranial LGG in this age group behaves aggressively. Pathologic sampling error failing to recognize higher-grade tumors does not seem to account for these poor outcomes. Aggressive management with maximally safe resection followed by adjuvant therapy should be strongly considered.
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies.
Toader C, Eva L, Costea D, Corlatescu A, Covache-Busuioc R, Bratu B Brain Sci. 2023; 13(12).
PMID: 38137148 PMC: 10741942. DOI: 10.3390/brainsci13121700.
Dao Trong P, Gluszak M, Reuss D, Deimling A, Wick A, Konig L J Neurooncol. 2023; 161(3):605-615.
PMID: 36648586 PMC: 9992027. DOI: 10.1007/s11060-022-04230-1.
Salari N, Fatahian R, Kazeminia M, Hosseinian-Far A, Shohaimi S, Mohammadi M Indian J Surg Oncol. 2022; 13(2):329-342.
PMID: 35782798 PMC: 9240140. DOI: 10.1007/s13193-022-01533-7.
Krigers A, Demetz M, Thome C, Freyschlag C Sci Rep. 2021; 11(1):17380.
PMID: 34462493 PMC: 8405625. DOI: 10.1038/s41598-021-96832-4.
Puthenpura V, Canavan M, Poynter J, Roth M, Pashankar F, Jones B Pediatr Blood Cancer. 2021; 68(7):e28970.
PMID: 33704901 PMC: 8221084. DOI: 10.1002/pbc.28970.